Pharmaron Beijing reports strong Q3 growth, strategic acquisition

Pharmaron Beijing Co., Ltd. released its third-quarter report for 2025, showing robust financial performance. Revenue for the nine months ended September 30, 2025, increased to RMB10,085,623,192.99, up 14.38% from the previous year. Net profit attributable to owners of the parent, excluding non-recurring gains or losses, rose by 32.04% to RMB1,034,061,391.98. Non-IFRS adjusted net profit attributable to owners of the parent increased by 10.76% to RMB1,226,549,336.09.

In a strategic move to enhance its drug discovery services, Pharmaron Beijing announced the acquisition of an 82.54% equity interest in Biortus for approximately RMB1.346 bn. Biortus specializes in Contract Research Organization (CRO) services for new drug R&D, particularly in structural biology and cryo-electron microscopy. This acquisition is expected to integrate Biortus's capabilities with Pharmaron's bioscience business, strengthening its early-stage biologics R&D services and leveraging AI technology for drug discovery.

Additionally, the company announced that Mr. Tsang Kwan Hung Benson will resign as an independent non-executive director, with Prof. Tsang King Fung nominated as his replacement. The board also approved proposed amendments to the Articles of Association, including the dissolution of the supervisory committee and the delegation of its functions to the audit committee.